JHS SVENDGAARD LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.65 INR | -1.94% |
|
-3.81% | -30.65% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,267 | 1,690 | 459.8 | 1,288 | 1,334 | 1,006 |
| Enterprise Value (EV) 1 | 3,055 | 1,720 | 483.2 | 1,128 | 1,315 | 770.7 |
| P/E ratio | 12.5 x | -248 x | -23.2 x | 102 x | -32.6 x | -6.62 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.32 x | 1.33 x | 0.32 x | 1.28 x | 1.55 x | 0.98 x |
| EV / Revenue | 2.17 x | 1.36 x | 0.34 x | 1.12 x | 1.52 x | 0.75 x |
| EV / EBITDA | 21.3 x | 44.3 x | 10.8 x | 18.6 x | 93.7 x | -67.8 x |
| EV / FCF | -10 x | -6.23 x | -2.87 x | -248 x | 6.65 x | 1.85 x |
| FCF Yield | -9.95% | -16% | -34.9% | -0.4% | 15% | 54% |
| Price to Book | 1.87 x | 0.96 x | 0.26 x | 0.68 x | 0.72 x | 0.58 x |
| Nbr of stocks (in thousands) | 60,900 | 60,900 | 60,900 | 64,400 | 64,900 | 64,900 |
| Reference price 2 | 53.65 | 27.75 | 7.550 | 20.00 | 20.55 | 15.50 |
| Announcement Date | 8/29/18 | 8/22/19 | 7/17/20 | 9/6/21 | 9/9/22 | 9/5/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,406 | 1,269 | 1,416 | 1,010 | 862.5 | 1,026 |
| EBITDA 1 | 143.2 | 38.83 | 44.8 | 60.48 | 14.03 | -11.37 |
| EBIT 1 | 75.32 | -31.83 | -29.16 | 3.554 | -46.05 | -69.82 |
| Operating Margin | 5.36% | -2.51% | -2.06% | 0.35% | -5.34% | -6.8% |
| Earnings before Tax (EBT) 1 | 384.2 | -20.45 | -58.43 | 9.678 | 1.03 | -218.4 |
| Net income 1 | 261.5 | -6.806 | -19.79 | 11.98 | -40.52 | -154.6 |
| Net margin | 18.6% | -0.54% | -1.4% | 1.19% | -4.7% | -15.07% |
| EPS 2 | 4.290 | -0.1118 | -0.3250 | 0.1952 | -0.6300 | -2.340 |
| Free Cash Flow 1 | -304.1 | -276.1 | -168.6 | -4.55 | 197.9 | 416.1 |
| FCF margin | -21.62% | -21.76% | -11.9% | -0.45% | 22.94% | 40.55% |
| FCF Conversion (EBITDA) | - | - | - | - | 1,409.85% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/29/18 | 8/22/19 | 7/17/20 | 9/6/21 | 9/9/22 | 9/5/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 30.4 | 23.4 | - | - | - |
| Net Cash position 1 | 212 | - | - | 160 | 18.4 | 235 |
| Leverage (Debt/EBITDA) | - | 0.7828 x | 0.5223 x | - | - | - |
| Free Cash Flow 1 | -304 | -276 | -169 | -4.55 | 198 | 416 |
| ROE (net income / shareholders' equity) | 16.9% | -0.94% | -2.66% | 0.7% | -2.18% | -8.94% |
| ROA (Net income/ Total Assets) | 2.59% | -0.93% | -0.79% | 0.09% | -1.28% | -1.9% |
| Assets 1 | 10,084 | 734 | 2,510 | 12,653 | 3,167 | 8,119 |
| Book Value Per Share 2 | 28.60 | 29.00 | 29.20 | 29.30 | 28.60 | 26.60 |
| Cash Flow per Share 2 | 0.9700 | 0.1300 | 0.1100 | 3.230 | 0.8100 | 5.900 |
| Capex 1 | 108 | 156 | 103 | 83.3 | 67.4 | 6.92 |
| Capex / Sales | 7.71% | 12.28% | 7.25% | 8.25% | 7.81% | 0.67% |
| Announcement Date | 8/29/18 | 8/22/19 | 7/17/20 | 9/6/21 | 9/9/22 | 9/5/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -30.65% | 16.92M | |
| -8.12% | 18.04B | |
| -7.57% | 4.02B | |
| +3.08% | 3.61B | |
| +1.49% | 2.62B | |
| -11.10% | 1.61B | |
| +42.48% | 1.28B | |
| +17.63% | 960M | |
| +20.97% | 795M | |
| +30.90% | 459M |
- Stock Market
- Equities
- JHS Stock
- Financials JHS Svendgaard Laboratories Limited